What Medtech AI does

MedTechAI Inc. is a Toronto-based private company that operates as the financing and commercialization arm of Oxford Immune Algorithmics (OIA), holding 28% of OIA with stated intent to increase its stake to 38%. The company is built around Algocyte, a handheld finger-prick-based diagnostic device co-developed with the UK National Health System, paired with a portable web-based platform that applies causal predictive AI algorithms to immune-system data to enable early detection of more than 20 health conditions and to deliver personalized, predictive medicine. The core technology is described as proprietary causal predictive modeling capable of outperforming generic machine learning on complex biological systems with limited data; the same algorithmic core was externally validated by winning Etihad's AI International Competition (run with HUB71 and Accenture) at 90%+ accuracy on cash-flow prediction, and the company has been invited to deploy it at Etihad Aviation Group scale.

MedTechAI goes to market through enterprise field sales supported by a network of regional hub and channel partners: HUB71 in the UAE for Asia/Africa/Middle East, Creative Destruction Lab in the US, SpinLab in Germany for the EU, Lacuna Diagnostics in China and the US, a UK hematology market leader controlling approximately one-third of the UK hematology market, and a Surrey smart-home developer for residential pilots. Reported commercial milestones to date consist of Letters of Intent rather than executed purchase orders — most notably a 3,000-device LOI from Lacuna Diagnostics China covering 1,000 hospitals with 600+ million annual patient visits, and integration terms with Lacuna Diagnostics US across 40 hospitals. The company has not disclosed revenue or product shipments.

Revenue mechanics combine hardware sales of the Algocyte device with potential subscription or platform recurring revenue from the web-based monitoring layer. Pricing is not publicly disclosed; the model is enterprise-channel driven rather than self-serve. Governance includes John Cullen as CEO, Andres Tinajero as CFO, Allan Bezanson as Director, and Pamela Winsor (former CMO of Medtronic) as Chair. The firm has been recognized as one of the 50 Most Promising Game-Changers in the Thames Valley (2020), nominated for the OBN Best Start-up Medtech Award (2020), and its underlying OIA technology won the Etihad AI International Competition in March 2021.

Name

Medtech AI

Legal name

MedTechAI Inc.

Website

https://medtechai.io

Company type

Private

Operating status

Operating

Short description

MedTechAI Inc. is a Toronto-based financing and commercialization vehicle for Oxford Immune Algorithmics, deploying the Algocyte handheld finger-prick diagnostic device and a causal predictive AI platform for early disease detection across hospital networks, smart-home pilots, and enterprise partners in the UK, UAE, US, China, and Germany.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

akta.pro secondary industry

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

Keywords

• Medical diagnostic devices
• Immune health monitoring
• Predictive healthcare analytics
• Handheld diagnostic technology
• AI medical diagnostics

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Algocyte Device Sales: Revenue from sale of handheld diagnostic devices (Algocyte) for early disease detection and immune health monitoring.
2. Platform/Subscription Services: Ongoing revenue from web-based platform access for immune system monitoring and predictive diagnostics, potentially subscription-based for continuous health monitoring services.

Go-to-market motion1 record

Distribution channels7 records

Marketing channels3 records

Core offering

MedTechAI commercializes the Algocyte handheld finger-prick diagnostic device co-developed with the UK NHS, paired with a portable web-based AI platform that monitors the user's immune system for rapid early detection of over 20 health diseases and conditions. The system delivers personalized and predictive medicine via causal predictive algorithms originated at Karolinska, incubated at the University of Oxford, and co-developed with the University of Cambridge.

Product overview

MedTechAI offers a single unified product portfolio centered on Algocyte, a handheld finger-prick-based diagnostic device co-developed with the UK National Health System (NHS). The device is supported by a portable web-based platform that uses AI algorithms to deliver personalized and predictive medicine by learning from and monitoring the user's immune system for early disease detection.

Differentiator

Problem solved

Functional benefit

Brands

• Algocyte: Handheld finger-prick-based device for rapid early detection of health diseases and conditions, co-developed with the UK National Health System (NHS). The device monitors and learns from the immune system to deliver personalized and predictive medicine.

Products and services

• Algocyte Diagnostic Device and Platform A handheld finger-prick-based device co-developed with the UK NHS that enables rapid early detection of over 20 health diseases and conditions by monitoring and learning from the user's immune system, paired with a portable web-based AI platform for personalized and predictive medicine. Designed for healthcare providers, diagnostic labs, hospital networks, and public health systems.

Quantifiable outcome

• 90%+ accuracy in predicting unpublished data compared to actual time series data
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core, minor and major.

• UK National Health System (NHS)coreStrategic or Co-development PartnerNHS co-developed and tested the Algocyte handheld finger-prick diagnostic device. This partnership provides regulatory validation and clinical testing environment for the immune health monitoring platform.
• UK Hematology Market LeadercoreChannel Partner/ Reseller/ DistributorUK reseller partner and leader in the hematology market in the UK, holding approximately 1/3 of the market share. This partnership provides established distribution channels in the UK healthcare market.
• Surrey Intelligent Home SystemminorStrategic or Co-development PartnerTen houses to open in Q1 2021 in Surrey with Algocyte embedded in the intelligent home system, representing integration of health monitoring into residential environments.
• HUB71majorStrategic or Co-development PartnerOIA UAE branch sponsored by UAE committed to invest and grow the company as a hub for Asia, Africa and the Middle East. Signed collaboration agreement with medical university (KIC). This represents a major international expansion initiative.
• Creative Destruction LabmajorStrategic or Co-development PartnerOIA was among 3 finalists among 400 startups in Creative Destruction Lab's US program. Medtech AI issued Letter of Intent to invest up to $6M in OIA over the next 2 years. Pam Winsor, CMO of Medtronic, joining the board.
• Lacuna Diagnostics (China)majorStrategic or Co-development PartnerLeading IT remote/mobile healthcare solution provider in China covering 1,000 hospitals with over 600 million patient visits per year and 1.5 million doctors. Letter of Intent signed requesting 3,000 devices initially.
• Lacuna Diagnostics (US)majorStrategic or Co-development PartnerServicing 40 hospitals in the US. Terms agreed to integrate Algocyte in their pathology pathway offerings.
• SpinLab - The HHL AcceleratorminorStrategic or Co-development PartnerSpinLab's and Leipzig's commercial partners and support to open European branch. Agreement with the Leipzig zoo to test technology applied to veterinary applications.
• KIC (Medical University)minorStrategic or Co-development PartnerMedical university in UAE with signed collaboration agreement, part of the HUB71 hub ecosystem for Asia, Africa and Middle East expansion.
• Etihad Group FinancemajorStrategic or Co-development PartnerEtihad Group Finance (owner of Etihad Airlines) held AI international competition with partners HUB71 and Accenture. OIA won the competition and will implement forecasting platform for Etihad's Aviation Group at global scale. Prize of $10,000 USD awarded.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Tasso Inc. Tasso produces at-home blood-collection devices paired with remote lab testing, addressing the same workflow as Algocyte — patient-friendly capillary sampling followed by connected diagnostic processing.
• Healthy.io: Healthy.io turns smartphone cameras into clinical-grade diagnostic readers (e.g., urinalysis, wound care). It is comparable to Algocyte in delivering clinical-grade diagnostics through a consumer/patient-friendly connected device format.
• Cue Health: Cue Health builds a handheld molecular diagnostic device for at-home and clinical use, with a portable reader and connected platform. It is the closest publicly comparable to Algocyte in form factor, connected-diagnostics business model, and enterprise-plus-consumer GTM.
• Everlywell: Everlywell offers at-home sample collection kits with connected lab testing for a panel of conditions. It competes with Algocyte on multi-condition at-home diagnostics, though Everlywell relies on mailed samples rather than an in-home reader.
• Babson Diagnostics: Babson has developed a finger-prick blood collection and diagnostics ecosystem aimed at retail and clinical settings. It competes with Algocyte on miniaturization of blood-based diagnostics and on retail/clinical partnerships.
• Yourbio Health: Yourbio Health (formerly Seventh Sense Biosystems) developed the TAP device for virtually painless capillary blood collection, targeting decentralized diagnostics and remote clinical trials — overlapping with Algocyte's finger-prick remote-diagnostic value proposition.
• Oxford Immune Algorithmics (OIA): OIA is the operating company that created Algocyte and the scientific entity in which MedTechAI holds a 28% stake. It is the most direct comparable because the underlying technology, product, and pipeline are the same; MedTechAI is essentially an investment vehicle into OIA.

Broad incumbents

• Roche Diagnostics: Roche Diagnostics is a global leader in clinical diagnostics, including POC and immunoassay platforms. It is a broad incumbent with overlapping capability in immune and infectious-disease testing that Algocyte must compete against or partner with for hospital adoption.
• Abbott Diagnostics: Abbott Diagnostics offers extensive POC and immunoassay product lines (e.g., i-STAT, Binax) and deep hospital distribution globally. It represents the type of entrenched incumbent MedTechAI/OIA must displace or co-exist with in the POC diagnostics market.

Emerging players

• SiPhox Health: SiPhox Health is building an at-home protein and hormone diagnostic platform with a connected reader. It targets a similar multi-biomarker home-diagnostic thesis to Algocyte, though at an earlier stage of commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medtech AI